Pulmonary Arterial Hypertension market
May 27, 2025
Gilead’s TRODELVY Shows PFS Benefit in 1L Metastatic TNBC; Otsuka’s Sibeprenlimab Gets FDA Priority Review for IgA Nephropathy; Liquidia Wins FDA Nod for YUTREPIA in PAH and PH-ILD; GSK’s BLENREP Combos Get CHMP Backing in Myeloma; Relief Therapeutics Receives FDA Rare Pediatric Disease Tag for RLF-TD011
Gilead’s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial Gilead Sciences has announced positive topline results from the Phase III ASCENT-03 trial of TRODELVY (sacituzumab govitecan-hziy) in first-line metastatic triple-negative breast cancer (mTNBC) patients who ar...
Read More...
Jun 17, 2024
WINREVAIR Approval for Pulmonary Arterial Hypertension Treatment: Is It A Game-Changer for Merck?
Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...
Read More...
Jun 13, 2022
New Clinical Developments in the Pulmonary Arterial Hypertension Treatment Domain
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, primarily affecting the small pulmonary arterioles. Pulmonary arterial hypertension is defined as mean pulmonary artery pressure greater than 25 mm Hg measured during right heart catheterization. The term Pulmonary arterial hypert...
Read More...
May 17, 2019
Pulmonary Arterial Hypertension Therapies
Pulmonary Arterial Hypertension (PAH) is a chronic, life-alarming disease that advances over time. It is a rare disease characterized by the increased blood pressure in the arteries of the lungs. It is somehow different from normal high pressure in a way that blood pressure rises only in the arteries that carry blo...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
